All In Biotech

Drug Trial Radar · NCT05985915

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjögren's Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

612

Actual

Start

Oct 27, 2023

Primary completion

Apr 22, 2033

Study completion Apr 22, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).

Conditions

  • Sjogrens Syndrome

Interventions

  • Ianalumab (VAY736)Drug

    Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use

  • PlaceboOther

    Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment-emergent AEs (TEAEs)/SAEsTime frame: Week 52 to Week 464

Locations

198 sites in 35 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Fullerton, California

  • Advanced Medical Research

    La Palma, California

  • Medvin Clinical Research

    Van Nuys, California

  • Bay Area Arthritis And Osteoporosis

    Brandon, Florida

  • GNP Research

    Cooper City, Florida

  • Sarasota Arthritis Res Ctr

    Sarasota, Florida

  • West Broward Rheumatology Associates Inc

    Tamarac, Florida

  • Augusta University Georgia

    Augusta, Georgia

  • North GA Rheumatology Group PC

    Suwanee, Georgia

  • Clin Invest Specialists Inc

    Orland Park, Illinois

  • University of Kansas Hospital

    Kansas City, Kansas

  • Ochsner Health System

    Baton Rouge, Louisiana

  • The John Hopkins Jerome L Greene Sjogren

    Baltimore, Maryland

  • Tufts School of Dental Medicine

    Boston, Massachusetts

  • Arthritis Osteoporosis Assoc of NM

    Las Cruces, New Mexico

  • NYU Langone Hospital - Long Island

    Mineola, New York

  • St Lawrence Health System

    Potsdam, New York

  • Arthritis and Osteoporosis

    Charlotte, North Carolina

  • On Site Clinical Solutions Llc

    Charlotte, North Carolina

  • Carolina Arthritis Associates

    Wilmington, North Carolina

  • STAT Research Inc

    Dayton, Ohio

  • RAO Research LLC

    Oklahoma City, Oklahoma

  • Altoona Center for Clin Res

    Duncansville, Pennsylvania

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Shelby Research LLC

    Memphis, Tennessee

  • Precision Comprehensive Research

    Colleyville, Texas

  • Baylor College Of Medicine

    Houston, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Houston Rheumatology and Arthrit

    Katy, Texas

  • First Outpatient Research Unit

    San Antonio, Texas

  • Advanced Rheumatology of Houston

    The Woodlands, Texas

  • Arthritis Northwest PLLC

    Spokane, Washington

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    Maroochydore, Queensland, Australia

  • Novartis Investigative Site

    Woodville South, South Australia, Australia

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.